Journal of Jilin University(Medicine Edition) ›› 2025, Vol. 51 ›› Issue (6): 1747-1754.doi: 10.13481/j.1671-587X.20250632
• Review • Previous Articles
Teng LIU,Ning ZHANG,Mingyuan HE(
),Guanghui CHENG(
)
Received:2025-03-12
Accepted:2025-05-15
Online:2025-11-28
Published:2025-12-15
Contact:
Mingyuan HE,Guanghui CHENG
E-mail:hemingyuan@jlu.edu.cn;chenggh@jlu.edu.cn
CLC Number:
Teng LIU,Ning ZHANG,Mingyuan HE,Guanghui CHENG. Research progress in treatment principles for endometrial cancer and its postoperative and postoperative recurrent radiotherapy[J].Journal of Jilin University(Medicine Edition), 2025, 51(6): 1747-1754.
Tab.1
Summary of common guidelines and treatment principles"
| Guideline | Low-risk | Intermediate-risk | High-intermediate risk | High-risk |
|---|---|---|---|---|
FIGO[ | Adjuvant radiotherapy is not recommended. | - | VBT alone demonstrated superior efficacy compared to EBRT. | EBRT is recommended for these patients. In Stage Ⅲ disease, the addition of chemotherapy to EBRT improves recurrence-free survival. |
ESGO-ESTRO-ESP[ | Adjuvant radiotherapy is not recommended. | VBT demonstrated efficacy in reducing vaginal recurrence rates. For patients under the age of 60, VBT may not be considered. | For patients with pathological nodal staging of pN0: VBT reduces the risk of vaginal recurrence. EBRT may be considered in cases with extensive LVSI or Stage Ⅱ disease. Adjuvant chemotherapy can be considered, particularly for patients with G3 histology and/or extensive LVSI. Omission of adjuvant therapy is an option, provided that close surveillance is maintained to ensure early detection and treatment of recurrence. For patients without nodal staging (cN0/pNx): EBRT is recommended for those with extensive LVSI and/or Stage Ⅱ disease. The addition of adjuvant chemotherapy should be considered, particularly for patients with G3 histology and/or extensive LVSI. For patients with G3 histology without LVSI or Stage Ⅱ G1 endometrioid carcinoma,VBT alone may be considered. | Concurrent chemoradiotherapy or sequential chemoradiotherapy is advised. Chemotherapy alone may also be considered as an alternative treatment strategy. |
| [1] | CROSBIE E J, KITSON S J, MCALPINE J N, et al. Endometrial cancer[J]. Lancet, 2022, 399(10333): 1412-1428. |
| [2] | SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. |
| [3] | 中国抗癌协会妇科肿瘤专业委员会. 子宫内膜癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 501-512. |
| [4] | 刘春静, 杨钰杰, 赵 薇, 等. 沉默CDC20基因通过抑制Wnt/β-连环蛋白信号通路对子宫内膜癌细胞增殖和细胞周期的影响[J]. 吉林大学学报(医学版), 2024, 50(5): 1305-1312. |
| [5] | ÅKESSON Å, ADOK C, DAHM-KÄHLER P. Recurrence and survival in endometrioid endometrial cancer-a population-based cohort study[J]. Gynecol Oncol, 2023, 168: 127-134. |
| [6] | 中华人民共和国国家卫生健康委员会. 子宫内膜癌诊治规范(2018年版)[J]. 肿瘤综合治疗电子杂志, 2020(4): 25-35. |
| [7] | BHATLA N, DENNY L. FIGO cancer report 2018[J]. Int J Gynecol Obstet, 2018, 143(S2): 2-3. |
| [8] | CONCIN N, MATIAS-GUIU X, VERGOTE I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma[J]. Int J Gynecol Cancer, 2021, 31(1): 12-39. |
| [9] | BANZ-JANSEN C, HELWEG L P, KALTSCHMIDT B. Endometrial cancer stem cells: where do we stand and where should we go?[J]. Int J Mol Sci, 2022, 23(6): 3412. |
| [10] | 陈晓军, 张剑峰, 陆 雯, 等. 子宫内膜癌手术治疗质量控制与评价标准中国专家共识(2024年版)[J]. 中国实用妇科与产科杂志, 2024, 40(6): 626-637. |
| [11] | EMONS G, VORDERMARK D. Adjuvant treatment for endometrial cancer[J]. Curr Opin Oncol, 2019, 31(5): 404-410. |
| [12] | JAMIESON A, MCALPINE J N. Molecular profiling of endometrial cancer from TCGA to clinical practice[J]. J Natl Compr Canc Netw, 2023, 21(2): 210-216. |
| [13] | COLOMBO N, CREUTZBERG C, AMANT F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up[J]. Int J Gynecol Cancer, 2016, 26(1): 2-30. |
| [14] | KLOPP A, SMITH B D, ALEKTIAR K, et al. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline[J]. Pract Radiat Oncol, 2014, 4(3): 137-144. |
| [15] | SUIDAN R S, HE W G, SUN C C, et al. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer[J]. Gynecol Oncol, 2019, 152(3): 439-444. |
| [16] | SORBE B, NORDSTRÖM B, MÄENPÄÄ J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study[J]. Int J Gynecol Cancer, 2009, 19(5): 873-878. |
| [17] | WORTMAN B G, CREUTZBERG C L, PUTTER H, et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy[J]. Br J Cancer, 2018, 119(9): 1067-1074. |
| [18] | SORBE B G, HORVATH G, ANDERSSON H, et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study: quality-of-life analysis[J]. Int J Gynecol Cancer, 2012, 22(7): 1281-1288. |
| [19] | BINGHAM B, ORTON A, BOOTHE D, et al. Brachytherapy improves survival in stage III endometrial cancer with cervical involvement[J]. Int J Radiat Oncol Biol Phys, 2017, 97(5): 1040-1050. |
| [20] | ELDREDGE-HINDY H B, EASTWICK G, ANNE P R, et al. Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer[J]. J Contemp Brachytherapy, 2014, 6(3): 262-270. |
| [21] | HUDDLESTON A, ZHEN S, QI L H, et al. The impact of a vaginal brachytherapy boost to pelvic radiation in stage III endometrial cancer[J]. J Contemp Brachytherapy, 2015, 7(2): 122-127. |
| [22] | HARKENRIDER M M, BLOCK A M, ALEKTIAR K M, et al. American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: a comprehensive review[J]. Brachytherapy, 2017, 16(1): 95-108. |
| [23] | RABINOVICH A, BERNARD L, NIAZI T M, et al. Para-aortic and pelvic radiotherapy, an effective and safe treatment in advanced-stage uterine cancer[J]. Anticancer Res, 2015, 35(5): 2893-2900. |
| [24] | RANDALL M E, FILIACI V, MCMEEKIN D S, et al. Phase Ⅲ trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer[J]. J Clin Oncol, 2019, 37(21): 1810-1818. |
| [25] | ABU-RUSTUM N, YASHAR C, AREND R, et al. Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2023, 21(2): 181-209. |
| [26] | SMALL W, BERIWAL S, DEMANES D J, et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy[J]. Brachytherapy, 2012, 11(1): 58-67. |
| [27] | KLOETZER K H, GÜNTHER R, WENDT T. The vaginal stump recurrence rate in endometrial carcinoma in relation to the target volume of postoperative HDR-afterloading brachytherapy[J]. Strahlenther Onkol, 1997, 173(1): 13-17. |
| [28] | CHOO J J, SCUDIERE J, BITTERMAN P, et al. Vaginal lymphatic channel location and its implication for intracavitary brachytherapy radiation treatment[J]. Brachytherapy, 2005, 4(3): 236-240. |
| [29] | GLATZER M, TANDERUP K, ROVIROSA A, et al. Role of brachytherapy in the postoperative management of endometrial cancer: decision-making analysis among experienced European radiation oncologists[J]. Cancers, 2022, 14(4): 906. |
| [30] | SORBE B, STRAUMITS A, KARLSSON L. Intravaginal high-dose-rate brachytherapy for stage Ⅰ endometrial cancer: a randomized study of two dose-per-fraction levels[J]. Int J Radiat Oncol Biol Phys, 2005, 62(5): 1385-1389. |
| [31] | NOORIAN F, ABELLANA R, ZHANG Y W, et al. Are 7.5 Gy × 2 fractions more efficient than 6 Gy × 3 in exclusive postoperative endometrial cancer brachytherapy? A clinical and dosimetrical analysis[J]. Radiother Oncol, 2023, 189: 109909. |
| [32] | CHINO J, ANNUNZIATA C M, BERIWAL S, et al. Radiation therapy for cervical cancer: executive summary of an ASTRO clinical practice guideline[J]. Pract Radiat Oncol, 2020, 10(4): 220-234. |
| [33] | STEWART A J, CORMACK R A, LEE H, et al. Prospective clinical trial of bladder filling and three-dimensional dosimetry in high-dose-rate vaginal cuff brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2008, 72(3): 843-848. |
| [34] | PALISOUL M, MUTCH D G. The clinical management of inoperable endometrial carcinoma[J]. Expert Rev Anticancer Ther, 2016, 16(5): 515-521. |
| [35] | BENTZEN S M, CONSTINE L S, DEASY J O, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 ): S3-S9. |
| [36] | POORVU P D, SADOW C A, TOWNAMCHAI K, et al. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes[J]. Int J Radiat Oncol Biol Phys, 2013, 85(5): 1262-1268. |
| [37] | VISWANATHAN A N, MOUGHAN J, MILLER B E, et al. NRG Oncology/RTOG 0921: a phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer[J]. Cancer, 2015, 121(13): 2156-2163. |
| [38] | 徐兴远, 王丹波. 复发性子宫内膜癌的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(5): 507-511. |
| [39] | LEGGE F, RESTAINO S, LEONE L, et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment[J]. Int J Gynecol Cancer, 2020, 30(2): 193-200. |
| [40] | 马晓欣, 向 阳, 张师前, 等. 复发性子宫内膜癌内分泌治疗中国专家共识(2024年版)[J]. 中国实用妇科与产科杂志, 2024, 40(1): 68-73. |
| [41] | 中国医师协会微无创医学专业委员会妇科肿瘤学组, 山东省抗癌协会妇科肿瘤分会. 复发性子宫内膜癌诊治的中国专家共识(2022年版)[J]. 中华肿瘤防治杂志, 2022, 29(21): 1517-1527. |
| [42] | 雒小佳, 胡海峰. 靶向放疗联合化疗改善局部复发性子宫内膜癌治疗的前瞻性研究[J]. 现代医学, 2025, 53(1): 43-49. |
| [43] | CHAPMAN C H, MAGHSOUDI K, LITTELL R D, et al. Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy[J]. Brachytherapy, 2017, 16(6): 1152-1158. |
| [44] | FOKDAL L, ØRTOFT G, HANSEN E S, et al. Toward four-dimensional image-guided adaptive brachytherapy in locally recurrent endometrial cancer[J]. Brachytherapy, 2014, 13(6): 554-561. |
| [45] | JHINGRAN A, BURKE T W, EIFEL P J. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy[J]. Int J Radiat Oncol Biol Phys, 2003, 56(5): 1366-1372. |
| [46] | KUNOS C A, BRINDLE J, WAGGONER S, et al. Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies[J]. Front Oncol, 2012, 2: 181. |
| [1] | Mingming JIN,Ran SUN,Minghui FAN,Lu GAO,Minjia SHENG. Research progress in application of umbilical cord mesenchymal stem cells in treatment of female reproductive system diseases [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 839-847. |
| [2] | Luyao WANG,Chenxi ZHAO,Wanze ZHANG,Linlin LIU. Second primary tracheal adenoid cystic carcinoma:A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 215-221. |
| [3] | Yongjing YANG,Tianyang KE,Shixin LIU,Xue WANG,Dequan XU,Tingting LIU,Ling ZHAO. Synergistic sensitization of apatinib mesylate and radiotherapy on hepatocarcinoma cells invitro [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1009-1015. |
| [4] | Jie YANG,Wubin HE,Ni AN,Wencong KONG,Rongjian SU,Xuezhe WANG. Regulatory effect of glucose-regulating protein 78 on radiotherapy sensitivity of liver cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(4): 888-895. |
| [5] | Yaoyu FENG, Chenglei ZHANG, Lijuan HOU, Yifu WANG, Xiuling WU, Yunhai MA. Effect of miR-222-3p knockdown targeting PTEN on 131I radiotherapy resistance of thyroid cancer and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 677-686. |
| [6] | Lan ZHENG,Songzhe PIAO,Ran XU,Xinyue WANG,Yixuan WANG,Zhenhua LIN,Yang YANG. Bioinformatics analysis based on effect of expression levels of m6A regulators on immune infiltration and prognosis of uterine corpus endometrial carcinoma [J]. Journal of Jilin University(Medicine Edition), 2021, 47(2): 438-452. |
| [7] | Jing WANG,Jing LIU,Xujing WEI,Yafei DU,Guiying FANG,Lin LI. Effects of oridonin on proliferation, migration, invasion and expression of lncRNA CCAT1 of endometrial carcinoma HEC-1B cells [J]. Journal of Jilin University(Medicine Edition), 2021, 47(2): 384-389. |
| [8] | WEI Xujing, LI Lin, ZHANG Hongzhen, WANG Jing, XU Jing. Effects of LncRNA CCAT1 on proliferation,invasion and migration of endometrial cancer cells through TGF-β1/smad signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2020, 46(05): 1016-1022. |
| [9] | WANG Zhi, HONG Li, LI Suting, ZENG Wanling. Analysis on endometrial cancer-related genes and candidate pathways based on GEO database bioinformatics methods [J]. Journal of Jilin University(Medicine Edition), 2020, 46(04): 804-809. |
| [10] | LIU Hui, MA Yunfei, LIU Bailong, LIU Min. Anlotinib combined with thoracic radiotherapy in treatment of recurrent and refractory small cell lung cancer: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2020, 46(02): 394-398. |
| [11] | LI Cheng, LIU Hui, GUO Liang, MA Yunfei, LIU Bailong, DONG Lihua. Radiotherapy combined with gefitinib in treatment of low-grade pulmonary mucoepidermoid carcinoma with EGFR sensitive mutation: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1436-1439. |
| [12] | ZHU Xiaopeng, LIU Bailong, GUO Liang, LIU Hui, LI Cheng, LIU Min, DONG Lihua. Long-term disease-free survival in patient with laryngeal small cell neuroendocrine carcinoma: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2019, 45(02): 405-409. |
| [13] | ZHONG Lili, ZHAO Yinlong, LI Bingjin, ZOU Xiaohan, CHENG Ziqian, CUI Ranji. Effects of MicroRNA-210 on growth and radiosensitivity of ovarian cancer cells [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 265-269. |
| [14] | SUN Xiaomei, XIA Wenming, JIANG Xin, CHEN Xiang, LI Tao, QU Yaqin. Comparison of dosimetry between RapidArc and 5F-IMRT in treatment of locally advanced pancreatic carcinoma [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 365-368. |
| [15] | WANG Qin, DU Liqing, WANG Yan, XU Chang, LI Jin, LIU Qiang. Inhibitory effect of Rb94 gene combined with radiotherapy on growth of esophageal carcinoma cells of tumor-bearing nude mice [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 220-224. |
|
||